Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. https://doi.org/10.1038/s41572-020-00224-3.
Article
PubMed
PubMed Central
Google Scholar
Yitian L, Deshi D. Cetuximab plus chemotherapy versus chemotherapy alone in recurrent or metastatic head and neck squamous cell carcinoma: a cost-effectiveness analysis. Cancer Manag Res. 2020;6(12):11383–90. https://doi.org/10.2147/CMAR.S272149.
Article
Google Scholar
Yoo SH, Ock CY, Keam B, Park SJ, Kim TM, Kim JH, Jeon YK, Chung EJ, Kwon SK, Hah JH, Kwon TK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS. Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment? Korean J Intern Med. 2019;34(6):1313–23. https://doi.org/10.3904/kjim.2017.397.
Article
PubMed
Google Scholar
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27. https://doi.org/10.1056/NEJMoa0802656.
Article
CAS
PubMed
Google Scholar
Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, Henry S, Schilf A, Bourhis J. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015;26:1941–7. https://doi.org/10.1093/annonc/mdv268.
Article
CAS
PubMed
Google Scholar
Guigay J, Fayette J, Mesia R, Lafond C, Saada-Bouzid E, Geoffrois L, Martin L, Cupissol D, Capitain O, Castanie H, Vansteene D, Schafhausen P, Dubos Arvis C, Even C, Sire C, Delhommeau M, Michel C, Bourhis J, Keilholz U, Auperin A. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37:6002. https://doi.org/10.1200/JCO.2019.37.15_suppl.6002.
Article
Google Scholar
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21. https://doi.org/10.1056/NEJMoa1809615.
Article
CAS
PubMed
Google Scholar
Kang C, Syed YY. Atezolizumab (in combination with Nab-paclitaxel): a review in advanced triple-negative breast cancer. Drugs. 2020;80(6):601–7. https://doi.org/10.1007/s40265-020-01295-y.
Article
CAS
PubMed
Google Scholar
Hu Y, Liu J, Cui P, Liu T, Piao C, Xu X, Zhang O, Xiao M, Lu Y, Liu X, Wang Y, Lu X. Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model. Cell Immunol. 2020;348: 104036. https://doi.org/10.1016/j.cellimm.2019.104036.
Article
CAS
PubMed
Google Scholar
Bernichon E, Tissot C, Bayle-Bleuez S, Rivoirard R, Bouleftour W, Forest F, Tinquaut F, Mery B, Fournel P. Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study. Bull Cancer. 2021;108(3):250–65. https://doi.org/10.1016/j.bulcan.2020.10.010.
Article
PubMed
Google Scholar
Pêtre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J. Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget. 2018;9(31):22038–46. https://doi.org/10.18632/oncotarget.
Article
PubMed
PubMed Central
Google Scholar
Tousif D, Sarathy V, Kumar R, Naik R. Randomized controlled study comparing efficacy and toxicity of weekly vs. 3-weekly induction chemotherapy in locally advanced head and neck squamous cell carcinoma. Front Oncol Front Oncol. 2020;10:1284. https://doi.org/10.3389/fonc.2020.01284.
Article
PubMed
Google Scholar
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.
Article
CAS
PubMed
Google Scholar
Gorenc M, Kozjek NR, Strojan P. Malnutrition and cachexia in patients with head and neck cancer treated with (chemo)radiotherapy. Rep Pract Oncol Radiother Jul-Aug. 2015;20(4):249–58. https://doi.org/10.1016/j.rpor.2015.03.001.
Article
Google Scholar
Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, Boothroyd D, Dimitrios CA. Weekly docetaxel, cisplatin, and cetuximab in palliative treatment of patients with squamous cell carcinoma of the head and neck. Oncologist. 2018;23(7):764-e86. https://doi.org/10.1634/theoncologist.2017-0618.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ. Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016–22. https://doi.org/10.1093/annonc/mdr367.
Article
CAS
PubMed
Google Scholar
Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018;29(4):1004–9. https://doi.org/10.1093/annonc/mdy040.
Article
CAS
PubMed
Google Scholar
Nakano K, Marshall S, Taira S, Sato Y, Tomomatsu J, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Kawabata K, Takahashi S. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma. Oral Oncol. 2017;73:21–6. https://doi.org/10.1016/j.oraloncology.2017.07.022.
Article
CAS
PubMed
Google Scholar
Narveson L, Kathol E, Rockey M, Henry D, Grauer D, Neupane P. Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. Med Oncol. 2016;33(10):107. https://doi.org/10.1007/s12032-016-0822-0.
Article
CAS
PubMed
Google Scholar
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67. https://doi.org/10.1056/NEJMoa1602252.
Article
CAS
PubMed
PubMed Central
Google Scholar
Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D’Amati G, Della Rocca C, Mezi S, Gelibter JA, Giusti R, Cortesi E, Ascierto PA, Nuti M, Marchetti P. The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy. Vaccines. 2020;8(2):203. https://doi.org/10.3390/vaccines8020203.
Article
CAS
PubMed Central
Google Scholar